• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
        • NTM Lung Disease
        • Bronchiectasis
        • Pulmonary Arterial Hypertension
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Programs
      • Pipeline
      • Clinical Trials
      • Our Research Team
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Feb 25, 2021
    Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
    --ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands--
  • Feb 24, 2021
    Insmed to Present at Two March Conferences
  • Feb 19, 2021
    Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)
    --TPIP Generally Safe and Well Tolerated in Healthy Volunteers--
  • Feb 16, 2021
    Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study
    --Call Scheduled for Friday, February 19, 2021, at 8:30 a.m. ET--
  • Feb 12, 2021
    Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021
  • Feb 5, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jan 5, 2021
    Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference
  • Jan 4, 2021
    Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease
    --First Patient Dosed in Post-Marketing Program Intended to Support Full FDA Approval of ARIKAYCE and sNDA in Newly Diagnosed Patients--
  • Dec 4, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Dec 2, 2020
    Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
    --First Patient Dosed in Global, Registrational Study of First-in-Class Treatment Candidate--
Show 5102550100 per page
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 63
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2022 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2022 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy